Gaps in dermatological research present potentially lucrative market opportunities for pharmaceutical companies. Patients that suffer from skin conditions and diseases also benefit. Effective treatments relieve irritating, chronic, and often painful symptoms, which improves their quality of life and lifts the psychological and social burden of a visible dermatological issue.
A clinical trial's operational efficiency depends on a solid oversight and response mechanism. Without vigilant monitoring, patient safety, data integrity, and the overall health of your trial come into jeopardy.
How to run a more efficient pediatric clinical trial: Although pediatric trials overall cost roughly the same as adult clinical trials according to one analysis, they generally produce a more modest return on investment. To ensure your neurodevelopmental or other pediatric study completes in a cost-effective, efficient manner, follow these tips:
C3 glomerulopathy (C3G), a rare kidney disease, affects only two or three people out of every one million. That’s only a couple people out of the entire population of San Jose, California or Austin, Texas. Although C3G only affects a select few, without treatment it can lead to severe kidney damage and failure, necessitating expensive dialysis or transplant. To date, there is no specific, effective therapy. As a CRO that understands the challenges involved in researching rare disease treatments, we’re here to help drug developers deliver the most effective clinical trials possible—on time and on budget. Speak with one of our rare disease experts today to find out how we can help you develop your next rare disease program.
Why Do So Many Clinical Trials Fall Behind? Clinical trials are not immune to missed deadlines and cost overruns. However, with proper advance planning, you can up the odds of success and avoid major glitches. Our studies show that about 33% of all clinical trials are behind schedule at any given moment. These trials under-perform due to operational failures; meaning, they’re behind schedule, over budget, or the data produced lacks the quality needed to support an approval.
Movement disorders such as Parkinson’s disease, ataxias, tremor, dystonia, tics, Tourette’s, and dozens of rare diseases, affect nearly 40 million Americans. They're usually chronic, often progressive, [...]
Eczema affects more people in the United States than diabetes (10.1 vs. 9.4 million)1,2. More than 8 million Americans have psoriasis.3 Considering how common some skin [...]
Have you ever put off talking to your significant other about expensive-but-necessary home repairs, for fear they'll hit the (leaking) roof? Most of us have, and [...]
Less than a year ago, FDA approved the first cannabinoid-derived drug, Epidiolex. It's a pivotal development for a few reasons: It's the first FDA-approved drug [...]
Each year, doctors diagnose about 1,000 Americans with cystic fibrosis, a rare hereditary disease that affects about 30,000 people in the United States. Thanks to advances [...]
"Microbiome" has become a consumer product buzzword, found in advertisements for soap and dozens of foods that contain "friendly bacteria." Meanwhile, the scientific community is discovering [...]
The numbers vary but multiple surveys confirm what we all know: patient recruitment is one of the most challenging and important aspects of running a clinical [...]